Aspirin and clopidogrel resistance: Should we worry about?

Minerva Medica

Volumn 101, Issue 1, 2010, Pages 35-47

  Cuisset, T ^a,b   Cayla, G ^c  

^a University of Marseille   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c NÎMES UNIVERSITY HOSPITAL   (France)

Author keywords

Aspirin; Coronary artery disease, prevention and control; Platelet aggregation inhibitors

Indexed keywords

11 OXOTHROMBOXANE B2; ACETYLSALICYLIC ACID; ALPHA2 INTEGRIN; BETA1 INTEGRIN; CLOPIDOGREL; COLLAGEN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; GLYCOPROTEIN IB; IBUPROFEN; NAPROXEN; PRASUGREL; PROSTAGLANDIN E1; PURINERGIC P2Y12 RECEPTOR; THROMBOXANE A2; THROMBOXANE B2; TICAGRELOR; VASODILATOR STIMULATED PHOSPHOPROTEIN; VON WILLEBRAND FACTOR;

ACUTE CORONARY SYNDROME; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; CLINICAL STUDY; CORONARY ARTERY DISEASE; CORONARY STENT; DNA POLYMORPHISM; DRUG ABSORPTION; DRUG EFFECT; DRUG EFFICACY; DRUG INFORMATION; DRUG MEGADOSE; GENETIC POLYMORPHISM; GOLD STANDARD; HEART PROTECTION; HUMAN; LOW DRUG DOSE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; OPTIMAL DRUG DOSE; PATIENT COMPLIANCE; PATIENT EDUCATION; PRESCRIPTION; RECURRENT DISEASE; REVIEW; SIGNAL TRANSDUCTION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE FUNCTION; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ASPIRIN; DRUG RESISTANCE; HUMANS; PLATELET AGGREGATION INHIBITORS; THROMBOEMBOLISM; TICLOPIDINE;

EID: 77952866908     PISSN: 00264806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (78)

1. Bhatt D, Topol EJ. Scientific and therapeutic advances in antiplatelet therapy. Nature Rev 2003;2:15-28. (Pubitemid 37361621)
2. Michelson AD. Platelet function testing in cardiovascular diseases. Circulation 2004;110:489-493
3. Patrono C. Aspirin resistance: definition, mechanisms and clinical read-outs. J Thromb Haemost 2003;1:1710-1713
4. Maclouf J, Folco G, Patrono C. Eicosanoids and iso-eicosanoids: constitutive, inducible and transcellular biosynthesis in vascular disease. Thromb Haemost 1998;79:691-705.
5. Karim S, Habib A, Levy-Toledano S, Maclouf J. Cyclooxygenase-1 and -2 of endothelial cells utilize exogenous or endogenous arachidonic acid for transcellular production of thromboxane. J Biol Chem 1996;271: 12042-12048 (Pubitemid 26157282)
6. Rocca B, Secchiero P, Ciabattoni G, Ranelletti FO, Catani L, Guidotti L et al. Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. Proc Natl Acad Sci USA 2002;99:7634-7639 (Pubitemid 34568743)
7. Weber AA, Zimmermann KC, Meyer-Kirchrath J, Schrör K. Cylcooxygenase-2 in human platelets as a possible factor in aspirin resistance. Lancet 1999;353:900. (Pubitemid 29126885)
8. Patrono C, Bachmann F, Baigent C, et al.. Expert consensus document on the use of antiplatelet agents. The Task Force on the Use of Antiplatelet Agents in Patients with Atherosclerotic Cardiovascular Disease of the European Society of Cardiology. Eur Heart J 2004;25:166-181
9. Kundu SK, Heilmann E, Sio R, Garcia C, Ostgaart R. Characterisation of an in vitro platelet function analyser, PFA-100TM. Clin Appl Thromb Hemost 1996;2:241-249 (Pubitemid 126699612)
10. Cattaneo M. Aspirin and clopidogrel. Efficacy, safety and the issue of drug resistance. Arterioscler Thromb Vasc Biol 2004;24:1980-1987
11. Marshall PW, Williams AJ, Dixon RM, et al.. A comparison of the effects of aspirin on bleeding time measured during the SimplateTM method and closure time measured using the PDA-100TM, in healthy volunteers. Br J Pharmacol 1997;44:151-155
12. Gum PA, Kottke-Marchant K, Poggio ED, Gurm H, Welsh PA, Brooks L et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001;88:230-235 (Pubitemid 32721947)
13. Malinin A, Spergling M, Muhlestein B, Steinhubl S, Serebruany V. Assessing aspirin responsiveness in subjects with multiple risk factors for vascular disease with a rapid platelet function analyzer. Blood Coagul Fibrinolysis 2004;15:295-301. (Pubitemid 38757056)
14. Malinin AI, Atar D, Callahan KP, McKenzie ME, Serebruany V. Effect of a single dose aspirin on platelets in humans with multiple risk factors for coronary artery disease. Eur J Pharmacol 2003;462:139-143 (Pubitemid 36183745)
15. Lordkipanidzé M, Pharand C, Schampaert E, Turgeon J, Palisaitis DA, Diodati JG. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J 2007;28:1702-1708 (Pubitemid 47227104)
16. Cotter G, Shemesh E, Zehavi M, Dinur I, Rudnick A, Milo O et al. Lack of aspirin effect:aspirin resistance or resistance to taking aspirin? Am Heart J 2004;147:293-300.
17. Cuisset T, Frere C, Quilici J, Gaborit B, Bali L, Poyet R et al. Aspirin noncompliance is the major cause of "aspirin resistance" in patients undergoing coronary stenting. Am Heart J 2009;157:889-893
18. Schwartz KA, Schwartz DE, Ghosheh K, Reeves MJ, Barber K, DeFranco A. Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction. Am J Cardiol 2005;95:973-975 (Pubitemid 40487749)
19. Tantry US, Bliden KP, Gurbel PA. Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. J Am Coll Cardiol 2005;46:1705-1709
20. Peters RJ, Mehta SR, Fox KA, Zhao F, Lewis BS, Kopecky SL et al. Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Trial Investigators. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes:observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation 2003;108:1682-1687
21. Burch JW, Stanford N, Majerus PW. Inhibition of platelet prostaglandin synthetase by oral aspirin. J Clin Invest 1978;61:314-319 (Pubitemid 8280401)
22. De Caterina R, Giannessi D, Bernini W, Gazzetti P, Michelassi C, L'Abbate A et al. Low-dose aspirin in patients recovering from myocardial infarction. Evidence for a selective inhibition of thromboxane-related platelet function. Eur Heart J 1985;6:409-417
23. Mehta S. Organisation to Assess Strategies for Ischemic Syndromes (OASIS)-7 Results, Oral Communication. ESC Congress, Barcelona 2009.
24. Needs CJ, Brooks PM. Clinical pharmacokinetics of the salicylates. Clin Pharmacokinet 1985;10:164-177
25. Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, DeMarco S, Tournier B et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001;345:1809-1817
26. Zimmermann N, Wenk A, Kim U, Kienzle P, Weber AA, Gams E et al. Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery. Circulation 2003;108:542-547 (Pubitemid 36961167)
27. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002;105:1650-1655 (Pubitemid 34298607)
28. Eikelboom JW, Hankey GJ, Thorn J, Bhatt DL, Steg PG, Montalescot G et al. Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) Investigators. Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid:determinants and effect on cardiovascular risk. Circulation 2008;118:1705-1712
29. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003;41:961-965 (Pubitemid 36315537)
30. Grotemeyer KH, Scharafinski HW, Husstedt IW. Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients. Thromb Res 1993;71:397-403.
31. Chen WH, Lee PY, Ng W, Tse HF, Lau CP. Aspirin resistance is associated with a high incidence of myonecrosis after nonurgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol 2004;43:1122-1126 (Pubitemid 38353000)
32. Grundmann K, Jaschonek K, Kleine B, Dichgans J, Topka H. Aspirin non-responder status in patients with recurrent cerebral ischemic attacks. J Neurol 2003;250:63-66 (Pubitemid 36206686)
33. Frelinger AL 3rd, Li Y, Linden MD, Barnard MR, Fox ML, Christie DJ et al. Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization. Circulation 2009;120:2586-2596
34. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. Jama 2005;293:2126-2130 (Pubitemid 40617065)
35. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting:response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003;107:2908-2913
36. Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Bhatt DL, Topol EJ. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005 18;45:246-251 (Pubitemid 40094733)
37. Collet JP, Silvain J, Landivier A, Tanguy ML, Cayla G, Bellemain A et al. Dose effect of clopidogrel reloading in patients already on 75-mg maintenance dose:the Reload with Clopidogrel Before Coronary Angioplasty in Subjects Treated Long Term with Dual Antiplatelet Therapy (RELOAD) study. Circulation 2008;118:1225-1233
38. Schwarz UR, Geiger J, Walter U, Eigenthaler M. Flow cytometry analysis of intracellular VASP phosphorylation for the assessment of activating and inhibitory signal transduction pathways in human platelets - definition and detection of ticlopidine/clopidogrel effects. Thromb Haemost 1999;82:1145-1152 (Pubitemid 29419734)
39. Aleil B, Ravanat C, Cazenave JP, Rochoux G, Heitz A, Gachet C. Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. J Thromb Haemost 2005;3:85-92. (Pubitemid 41647119)
40. von Beckerath N, Pogatsa-Murray G, Wieczorek A, Sibbing D, Schömig A, Kastrati A. Correlation of a new point-of-care test with conventional optical aggregometry for the assessment of clopidogrel responsiveness. Thromb Haemost 2006;95:910-911
41. Sibbing D, Braun S, Jawansky S, Vogt W, Mehilli J, Schömig A et al. Assessment of ADP-induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopidogrel treatment. Thromb Haemost 2008;99:121.
42. Matetzky S, Shenkman B, Guetta V, Shechter M, Bienart R, Goldenberg I et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004;109:3171-3175
43. Cuisset T, Frere C, Quilici J, Barbou F, Morange PE, Hovasse T et al. High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J Thromb Haemost 2006;4:542-549
44. Buonamici P, Marcucci R, Migliorini A, Gensini GF, Santini A, Paniccia R et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 2007;49:2312-2317 (Pubitemid 46891710)
45. Hochholzer W, Trenk D, Bestehorn HP, Fischer B, Valina CM, Ferenc M et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 2006;48:1742-1750 (Pubitemid 44648629)
46. Muller I, Besta F, Schulz C, Massberg S, Schonig A, Gawaz M. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost 2003;89:783-787 (Pubitemid 36603418)
47. Gurbel PA, Bilden KP, Guyer K, Cho PW, Zaman KA, Kreutz RP et al. Platelet reactivity in patients and recurrent events post-stenting:results of the PREPARE POST-STENTING Study. J Am Coll Cardiol 2005;46:1820-1826 (Pubitemid 41579802)
48. Geisler T, Langer H, Wydymus M, Gohring K, Zurn C, Bigalke B et al. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J 2006;27:2420-2425 (Pubitemid 44522148)
49. Bonello L, Paganelli F, Arpin-Bornet M, Auquier P, Sampol J, Dignat-George F et al. asodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of post-procedural major adverse cardiovascular events. J Thromb Haemost 2007;5:1630-1636 (Pubitemid 47091403)
50. Cayla G, Macia JC, Rabesandratana H, Roubille F, Gervasoni R, Pasquie JL et al. Flow cytometric assessment of vasodilator-stimulated phosphoprotein: prognostic value of recurrent cardiovascular events after acute coronary syndromes. Arch Cardiovasc Dis 2008;101:743-751
51. Frere C, Cuisset T, Quilici J, Camoin L, Carvajal J, Morange PE et al. ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome. Thromb Haemost 2007;98:838-843 (Pubitemid 47555077)
52. Marcucci R, Gori AM, Paniccia R, Giusti B, Valente S, Giglioli C et al. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay:a 12-month follow-up. Circulation 2009;119:237-242
53. Patti G, Nusca A, Mangiacapra F, Gatto L, D'Ambrosio A, Di Sciascio G. Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study. J Am Coll Cardiol 2008;52:1128-1133
54. Price MJ, Endemann S, Gollapudi RR, Valencia R, Stinis CT, Levisay JP et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 2008;29:992-1000. (Pubitemid 351844676)
55. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel:relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 2009;119:2553-2560
56. Collet JP, Hulot JS, Pena A, Villard E, Esteve JB, Silvain J et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction:a cohort study. Lancet 2009;373:309-317
57. Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Meneveau N et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009;360:363-375
58. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009;360:354-362
59. Sibbing D, Stegherr J, Latz W, Koch W, Mehilli J, Dorrler K et al. Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. Eur Heart J 2009;30:916-922
60. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramírez C, Sabaté M, Jimenez-Quevedo P et al. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 2005;54:2430-2435 (Pubitemid 41134272)
61. Soffer D, Moussa I, Harjai KJ, Boura JA, Dixon SR, Grines CL et al. Impact of angina class on inhibition of platelet aggregation following clopidogrel loading in patients undergoing coronary intervention:do we need more aggressive dosing regimens in unstable angina? Catheter Cardiovasc Interv 2003;59:21-25
62. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Alfonso F, Macaya C, Bass TA et al. Platelet aggregation according to body mass index in patients undergoing coronary stenting:should clopidogrel loading-dose be weight adjusted? J Invasive Cardiol 2004;16:169-174 (Pubitemid 38456448)
63. Angiolillo DJ, Bernardo E, Ramirez C, Costa MA, Sabaté M, Jimenez-Quevedo P et al. Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment. J Am Coll Cardiol 2006;48:298-304. (Pubitemid 44026661)
64. Lau WC, Waskell LA, Watkins PB, Neer CJ, Horowitz K, Hopp AS et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregations new drug-drug interaction. Circulation 2003;107:32-37 (Pubitemid 36070929)
65. Siller-Matula JM, Lang I, Christ G, Jilma B. Calcium-channel blockers reduce the antiplatelet effect of clopidogrel. J Am Coll Cardiol 2008;52:1557-1563
66. Gilard M, Arnaud B, Cornily JC, Le Gal G, Lacut K, Le Calvez G et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole Clopidogrel Aspirin) study. J Am Coll Cardiol 2008;51:256-260
67. Juurlink DN, Gomes T, Ko DT, Szmitko PE, Austin PC, Tu JV et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009;180:713-718
68. Ho PM, Maddox TM, Wang L, Fihn SD, Jesse RL, Peterson ED et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA. 2009;301:937-944
69. O'Donoghue ML, Braunwald E, Antman EM, Murphy SA, Bates ER, Rozenman Y et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor:an analysis of two randomised trials. Lancet 2009;374:989-997
70. Bhatt DL. COGENT:A prospective, randomized, placebo-controlled trial of omeprazole in patients receiving aspirin and clopidogrel. Presented at:Transcatheter Cardiovascular Therapeutics; September 24, 2009;San Francisco, Calif.
71. Cuisset T, Frere C, Quilici J, Poyet R, Gaborit B, Bali L et al. Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose:the PACA (Proton Pump Inhibitors and Clopidogrel Association) prospective randomized study. J Am Coll Cardiol 2009;54:1149-1153
72. Bonello L, Camoin-Jau L, Arques S, Boyer C, Panagides D, Wittenberg O et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance:a multicenter randomized prospective study. J Am Coll Cardiol 2008;51:1404-1411
73. Cuisset T, Frere C, Quilici J, Morange PE, Mouret JP, Bali L et al. Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders:a prospective, randomized study. JACC Cardiovasc Interv 2008;1:649-653
74. Valgimigli M, Campo G, de Cesare N, Meliga E, Vranckx P, Furgieri A et al. Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel (3T/2R) Investigators. Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention:results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel study. Circulation 2009;119:3215-3222
75. Montalescot G, Sideris G, Meuleman C, Bal-dit-Sollier C, Lellouche N, Steg PG et al. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes:the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. J Am Coll Cardiol 2006;48:931-938
76. Montalescot G, Wiviott SD, Braunwald E, Murphy SA, Gibson CM, McCabe CH et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38):double-blind, randomised controlled trial. Lancet 2009;373:723-731
77. Wiviott SD, Braunwald E, Angiolillo DJ, Meisel S, Dalby AJ, Verheugt FW et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation 2008;118:1626-1636
78. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-1057